Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Aim Immunotech Inc (AIM)

Aim Immunotech Inc (AIM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Insider Purchase: CEO & President of $AIM (AIM) Buys 60,110 Shares Quiver Quantitative, Inc. - Wed Nov 20, 10:08PM CST

Thomas K Equels, the CEO & President of $AIM ($AIM), bought 60,110 shares of the company on 11-20-2024. This trade was reported by Quiver Quantitative using data from a recent SEC filing. This increased...

AIM : 0.2000 (+9.29%)
AIM ImmunoTech Inc. Announces Publication of Promising Data from Roswell Park Phase 1 Study on Ampligen® for Early-Stage Triple-Negative Breast Cancer Quiver Quantitative, Inc. - Tue Nov 19, 5:20PM CST

AIM ImmunoTech announces promising Phase 1 trial results for Ampligen® in early-stage triple-negative breast cancer.Quiver AI SummaryAIM ImmunoTech Inc. announced the publication of promising data from...

AIM : 0.2000 (+9.29%)
AIM ImmunoTech Announces Publication of Breast Cancer Data from Roswell Park Comprehensive Cancer Center in The Journal for ImmunoTherapy of Cancer GlobeNewswire - Tue Nov 19, 7:00AM CST

AIM : 0.2000 (+9.29%)
AIM ImmunoTech Inc. Reports Progress in Ampligen® Clinical Development for Pancreatic Cancer and Other High-Need Indications Quiver Quantitative, Inc. - Fri Nov 15, 4:48PM CST

AIM ImmunoTech reports progress on Ampligen® trials, particularly in pancreatic cancer, and hosts a conference call today.Quiver AI SummaryAIM ImmunoTech Inc. has announced continued progress in its clinical...

AIM : 0.2000 (+9.29%)
AIM ImmunoTech Reports Third Quarter 2024 Financial Results and Provides Corporate Update GlobeNewswire - Fri Nov 15, 6:29AM CST

AIM : 0.2000 (+9.29%)
AIM ImmunoTech to Discuss Third Quarter 2024 Financial Results on November 15, 2024 and Host Conference Call and Webcast GlobeNewswire - Wed Nov 6, 8:00AM CST

AIM : 0.2000 (+9.29%)
AIM ImmunoTech to Participate in the 2024 Healthcare Virtual Summit, Presented by Maxim Group LLC GlobeNewswire - Wed Oct 9, 8:00AM CDT

AIM : 0.2000 (+9.29%)
AIM ImmunoTech Granted U.S. Patent for Ampligen® for the Treatment of Endometriosis GlobeNewswire - Thu Oct 3, 7:45AM CDT

AIM : 0.2000 (+9.29%)
Biotech Sector Delivering Increased Optimism in Battle Against Pancreatic Cancer BayStreet.ca - Fri Mar 17, 2023

USA News Group – Optimism is on the rise as the American Cancer Society is reporting that the five-year survival rate for those diagnosed with pancreatic has increased to 12%—representing an increase...

NVS : 103.09 (-0.17%)
ONCY : 0.9985 (-5.80%)
ONC.TO : 1.40 (-5.41%)
RHHBY : 35.1300 (-0.79%)
BMEA : 6.28 (-2.18%)
AIM : 0.2000 (+9.29%)
AZN : 63.20 (-0.94%)
Rise in Biotech Innovations Generating Hope as Pancreatic Cancer Survival Rates Climb FinancialNewsMedia - Tue Mar 14, 2023

FN Media Group Presents USA News Group News Commentary   Vancouver, BC – March 14, 2023 – USA News Group  –  Optimism is on the rise as the American Cancer Society is reporting that the five-year...

NVS : 103.09 (-0.17%)
ONCY : 0.9985 (-5.80%)
ONC.TO : 1.40 (-5.41%)
RHHBY : 35.1300 (-0.79%)
BMEA : 6.28 (-2.18%)
AIM : 0.2000 (+9.29%)
AZN : 63.20 (-0.94%)

Barchart Exclusives

Stocks Slip Before the Open on Nvidia’s Disappointing Forecast and Ukraine Jitters, U.S. Economic Data on Tap Barchart - 53 minutes ago
December S&P 500 E-Mini futures (ESZ24) are down -0.31%, and December Nasdaq 100 E-Mini futures (NQZ24) are down -0.43% this morning as a disappointing revenue forecast from Nvidia and concerns about escalating Russia-Ukraine tensions dampened sentiment. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot